Washington, Oct 21 (BUS): The US Food and Drug Administration (FDA) on Wednesday approved the use of heterogeneous Covid-19 vaccines as part of the expansion in the use of boosters.
The agency has approved the use of a booster dose of Moderna at least six months after the first two doses for people over 65 and younger who are considered to be at high risk because of their health or occupation, the dpa reports.
A booster dose of the Johnson & Johnson vaccine, which must be given only once, is approved two months after the end of the statute for people 18 years of age or older.
The FDA has also approved the use of “each of the available COVID-19 vaccines as a heterogeneous (or “mixed and matched”) booster dose in eligible individuals” following the statute at a different dose.
“The availability of these authorized enhancers is important for continued protection against COVID-19,” said Janet Woodcock, acting commissioner of the Food and Drug Administration.
Expansion of the use of boosters “depends on available data and information and follows input from members of our advisory committee who have been supportive of the use of a booster dose of these vaccines in eligible populations,” said Peter Marks, director of the Food and Drug Administration’s Center for Biological Evaluation and Research.
“We will work to collect additional data as quickly as possible to assess the benefits and risks of using booster doses in additional populations and plan to update the healthcare community and the public with our determination in the coming weeks,” Marks added.